enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 156,200 shares, a growth of 31.3% from the August 15th total of 119,000 shares. Approximately 1.0% of the company’s shares are short sold. Based on an average daily volume of 134,100 shares, the short-interest ratio is presently 1.2 days.

enGene Stock Up 1.5 %

NASDAQ ENGN traded up $0.10 on Monday, reaching $6.79. The stock had a trading volume of 36,328 shares, compared to its average volume of 85,947. The company has a market capitalization of $299.91 million, a price-to-earnings ratio of -4.09 and a beta of -0.68. The company has a current ratio of 19.52, a quick ratio of 42.80 and a debt-to-equity ratio of 0.09. enGene has a 1 year low of $4.94 and a 1 year high of $43.00. The business has a 50 day moving average price of $7.45 and a 200 day moving average price of $11.35.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. On average, analysts forecast that enGene will post -1.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Altitude Crest Partners Inc. bought a new position in enGene in the first quarter valued at about $2,039,000. SR One Capital Management LP bought a new position in enGene during the 2nd quarter worth approximately $4,715,000. Omega Fund Management LLC acquired a new position in enGene during the fourth quarter valued at approximately $10,441,000. Logos Global Management LP boosted its position in shares of enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after purchasing an additional 400,000 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new position in shares of enGene in the 1st quarter valued at $17,095,000. Institutional investors own 64.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ENGN shares. Oppenheimer assumed coverage on shares of enGene in a research report on Wednesday, August 28th. They set an “outperform” rating and a $30.00 target price on the stock. Morgan Stanley reiterated an “overweight” rating and set a $40.00 target price on shares of enGene in a research note on Wednesday, September 11th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, enGene presently has an average rating of “Buy” and an average price target of $33.67.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.